Are we using personalized treatment for patients with myelofibrosis?
ESH eLearning, Alessandro Vannucchi, 219254
Epigenetics in myeloproliferative neoplasms
ESH eLearning, Mary-Frances McMullin, 219251
Dissecting the molecular genetics of MPN
ESH eLearning, Ann Mullally, 219252
Stem cell depletion therapy is needed to change the natural history of the MPNs
ESH eLearning, Ronald Hoffman, 219253
Somatic mutations and clonal relationships
ESH eLearning, Peter Campbell, 219247
MPN Drivers: from active JAK2 and TpoR mutants to rogue calreticulin and their role in progression
ESH eLearning, Stefan N Constantinescu, 219248
Role of epigenetic dysregulation in MPN pathogenesis
ESH eLearning, Ross L. Levine, 219249
Megakaryocyte differentiation therapy in the MPNs
ESH eLearning, John D. Crispino, 219250
Antibodies & antibody conjugates
ESH eLearning, Wendy Stock, 219267
CAR T-cells
ESH eLearning, Noëlle Frey, 219268
Treatment of poor ELN risk AML
ESH eLearning, Richard Schlenk, 219258
Salvage therapy
ESH eLearning, Arnold Ganser, 219259
FLT3 inhibitors
ESH eLearning, M Levis, 219260
IDH inhibitors
ESH eLearning, Eytan Stein, 219261
Therapy of acute promyelocytic leukemia
ESH eLearning, Lionel Adès, 219262
Gemtuzumab Ozogamicin
ESH eLearning, Alan Burnett, 219263
Maintenance therapy after transplantation
ESH eLearning, Charles Craddock, 219264
Low-intensity treatments
ESH eLearning, Hervé Dombret, 219265
Tumor target antigens in AML
ESH eLearning, Marion Subklewe, 219266
Diagnosis of ph-like ALL
ESH eLearning, Charles Mullighan, 219255
Leukemic stem cells modulate the bone marrow microenvironment
ESH eLearning, Bonnet Dominique, 219256
Is transplant needed to cure Ph+ ALL in patients who achieve MRD negativity? - No
ESH eLearning, Farhad Ravandi-Kashani, 219257
Understanding gene-gene interactions via machine learning: Pandora’s box?
ESH eLearning, Andrew Wei, 226246
Improving the activity of BH3 mimetic venetoclax: a case study
ESH eLearning, Andrew Wei, 226247
Clinical trials investigating venetoclax combinations for AML
ESH eLearning, Andrew Wei, 226248
An overview of 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias
ESH eLearning, Arnold Ganser, 226249
The devastating effects of relapsed or refractory AML
ESH eLearning, Arnold Ganser, 226250
From bench to the bedside: understanding the genetic changes in AML
ESH eLearning, Arnold Ganser, 226251
Finding the right targets for CAR T-cell therapy in AML
ESH eLearning, Arnold Ganser, 226252
Midostaurin: the first drug to receive approval for AML since 2000
ESH eLearning, Arnold Ganser, 226253
Overcoming the issues with clinical trial recruitment
ESH eLearning, Arnold Ganser, 226254
Transplantation clinical trial network to build available prospective studies on AML
ESH eLearning, Charles Craddock, 226255
Current understandings of ALL approaches
ESH eLearning, Charles Craddock, 226256
Challenges with the identification of ALL subtypes
ESH eLearning, Charles Craddock, 226257
Improving response to ALL therapies
ESH eLearning, Charles Craddock, 226258
Minimal residual disease: a key determinant of ALL treatment response
ESH eLearning, Charles Craddock, 226259
Increasing the effectiveness of ALL therapies
ESH eLearning, Charles Craddock, 226260
Combination therapy for the treatment of AML
ESH eLearning, Christoph Röllig, 226261
Applying the right therapies to the right AML patient population
ESH eLearning, Christoph Röllig, 226262
MRD detection techniques in AML: pros and cons
ESH eLearning, Christoph Röllig, 226263
Immunotherapies for the treatment of AML
ESH eLearning, Christoph Röllig, 226264
Managing AML in elderly patients
ESH eLearning, Christoph Röllig, 226265
Biological rationales when determining AML therapies
ESH eLearning, Christoph Röllig, 226266
Targeting IDH mutations for the treatment of AML
ESH eLearning, Eytan Stein, 226267
Toxicity profiles of IDH inhibitors: are they as intimidating as they seem?
ESH eLearning, Eytan Stein, 226268
Primary and secondary resistance in AML
ESH eLearning, Eytan Stein, 226269
Encouraging patients to participate in AML trials
ESH eLearning, Eytan Stein, 226270
The latest clinical trials into novel AML therapies
ESH eLearning, Eytan Stein, 226271
The complications of treating elderly patients with AML
ESH eLearning, Gail Roboz, 226272
Managing relapse in AML: the role of MRD
ESH eLearning, Gail Roboz, 226273
Combining existing drugs for the creation of novel AML therapies
ESH eLearning, Gail Roboz, 226274
Increasing AML clinical trial participation rates
ESH eLearning, Gail Roboz, 226275
The challenges of choosing the right target antigen in AML compared to ALL
ESH eLearning, Marion Subklewe, 226276
Exciting immunotherapy clinical trials for the management of AML
ESH eLearning, Marion Subklewe, 226277
How can we improve CAR T-cell therapy?
ESH eLearning, Marion Subklewe, 226278
Immunotherapy clinical trial participation in R/R AML
ESH eLearning, Marion Subklewe, 226279
Involving the patient is a key part of cancer treatment
ESH eLearning, Mark Levis, 226280
CAR T-cell therapy and ALL: the current landscape
ESH eLearning, Noelle Frey, 226281
The CAR T-cell therapy race
ESH eLearning, Noelle Frey, 226282
The importance of MRD assessment in all phases of ALL treatment
ESH eLearning, Noelle Frey, 226283
Next-generation methodologies: the future for MRD monitoring in ALL?
ESH eLearning, Wendy Stock, 226284
Emerging novel approaches for ALL: inotuzumab ozogamicin
ESH eLearning, Wendy Stock, 226285
Support systems are a crucial factor in ALL treatment
ESH eLearning, Wendy Stock, 226286
Bone marrow transplant in red cell disorders
ESH eLearning, eliane Gluckman, 219043
Sickle cell disease pathophysiology
ESH eLearning, Jacques Elion, 219038
ESH eLearning, Maria Domenica Cappellini, 219039
Malaria and red cell disorders
ESH eLearning, Michael Lanzer, 219040
Epidemiology of red cell disorders
ESH eLearning, Frédéric B. Piel, 219041
Red cell senescence and storage lesions
ESH eLearning, Giel Bosman, 219042
Erythroid niche and erythroblast maturation
ESH eLearning, Mohandas Narla, 219034
Epigenetics in erythropoiesis
ESH eLearning, Gordon D. Ginder, 219035
Heme synthesis and iron metabolism
ESH eLearning, Laurent Gouya, 219036
Red cells and oxidative stress
ESH eLearning, Lucia De Franceschi, 219037
Richter transformation in the elderly patient:molecular origin and new strategies for improved therapies
ESH eLearning, Davide Rossi, 212197
Targeting the DNA Damage Response in high-risk lymphoma: biology and insights for future, less toxic approaches of therapy
ESH eLearning, Hans Reinhardt, 212198
Double hit and other types of high-risk lymphoma:molecular features and optimal management in the elderly patient
ESH eLearning, Paul Hamlin, 212199
Biology of AML at older age
ESH eLearning, Terrence N. Wong, 212185
Therapeutic management of the so-called “fit” older patient with AML
ESH eLearning, Bob Löwenberg, 212186
Management of the unfit patient with AML
ESH eLearning, Gert Ossenkoppele, 212187
The older patient with ALL
ESH eLearning, Hervé Dombret, 212188
Alloegeneic stem cell transplantation at older age
ESH eLearning, Nicolaus Kröger, 212189
Clonal evolution of multiple myeloma
ESH eLearning, Nikhil Munshi, 212190
MGUS and MGUS transition to myeloma, what do we need to do?
ESH eLearning, Irene Ghobrial, 212191
Multiple myeloma in the elderly, a particular challenge in light of numerous novel agents.
ESH eLearning, Jesús F. San-Miguel, 212192
Clonal evolution in malignant lymphoma
ESH eLearning, Jude FITZGIBBON, 212193
Management of indolent lymphoma in the elderly patient
ESH eLearning, Loretta Nastoupil, 212194
Management of comorbidity and specific adverse events in the era of novel kinase inhibitors (ibrutinib, idelalisib, venetoclax) for lymphoid malignancies
ESH eLearning, Farrukh Awan, 212195
Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma
ESH eLearning, Loretta Nastoupil, 212196
DNA damage, a driving force of aging
ESH eLearning, Björn Schumacher, 212174
Clonal hematopoiesis
ESH eLearning, Benjamin Ebert, 212175
Clonal hematopoiesis
ESH eLearning, George Vassiliou, 212176
Selection of TP53 mutant clones following chemotherapy
ESH eLearning, Terrence N. Wong, 212177
Aging stem cells and stress
ESH eLearning, Michael Milsom, 212178
Anemia at older age
ESH eLearning, Nancy Berliner, 212179
Microenvironment and MDS
ESH eLearning, Rebekka Schneider, 212180
Biology of MDS
ESH eLearning, Benjamin Ebert, 212181
Management of high grade MDS
ESH eLearning, Pierre Fenaux, 212182
Management of CMML and other MDS/MPN entities
ESH eLearning, Raphael Itzykson, 212183
Assessing the aging individual with hematologic disorders: How geriatric assessment can define the fitness of an older patient
ESH eLearning, Tanya Wildes, 212184
The pathology of marginal zone lymphomas
ESH eLearning, German Ott, 210034

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.

Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.

Save Settings